Magazine Article | February 7, 2018

Can Private Money Stop The Slump In Global R&D Funding?

Source: Life Science Leader

By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter

Worldwide, there has been a slowdown, or even a decline, in the growth of public funding for healthcare R&D from public sector agencies and multilateral organizations over the past decade, according to the second Brookings Private Sector Global Health R&D Project from the Center for Technology Innovation at Brookings, titled Private Sector Investment in Global Health R&D: Spending Levels, Barriers, and Opportunities.

The decrease in public funding can impact private sector R&D investment, because public funding often provides support for the basic research essential to the innovation that in turn is an investment target for private money. Cutbacks on spending also can have an impact on public/private partnerships. And the impact is going to be the greatest on the drugs for global R&D – the treatments for diseases most prevalent in developing markets.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: